The year 2013 is likely to be remembered as a very good year when it comes to re­search related to multiple myeloma.

Previous years have witnessed re­search shedding new light on existing my­e­lo­ma ther­a­pies, as well as addi­tional re­search about poten­tial new ther­a­pies.

But, in the past, most of the im­por­tant new ther­a­pies that were being re­searched were from existing classes of ther­apy, making them less likely to offer dramatic im­prove­ments in the treat­ment of the dis­ease.

In 2013, not only was there more re­search about existing ther­a­pies, and more re­search about …

Initial results from a Phase 1 clin­i­cal trial show prom­ise for SAR650984 as a thera­peutic option for heavily pre­treated multiple myeloma patients.

SAR650984 is one of several poten­tial new anti-myeloma agents for which clin­i­cal results were first pre­sented at the American Society of Hematology (ASH) meeting last week.

The results were pre­sented by Dr. Joseph Mikhael from the Mayo Clinic in Scottsdale, Arizona, who told The Beacon, “This drug was hands down the most promising new agent at ASH for myeloma.”

Dr. Mikhael further ex­plained, “The re­sponse­ rates were impressive, especially in …

This Monday was the third day of the 2013 American Society of Hema­tol­o­gy (ASH) annual meeting, which was held in New Orleans.

More than any other day of the conference, Monday was packed with im­por­tant myeloma pre­sen­ta­tions, from 7:00 in the morning until almost 8:00 in the eve­ning.

This ASH update will summarize the oral pre­sen­ta­tion sessions about treat­ment-related myeloma studies that were held Monday morning. An ASH update that was pub­lished on Wednesday focused on the sessions that were held Monday afternoon and evening.

Monday morning started with three simultaneous …

This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.

Myeloma-related presentations were made during several sessions yesterday.

Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.

The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as pre­clin­i­cal and clin­i­cal studies testing new and existing treat­ments for myeloma.

During the session, research results were made avail­able for review by meeting attendees in the form …

The Beacon con­tinues today with its ‘ASH preview’ series about mye­lo­ma re­search that will be pre­sented at the American Society of Hema­tol­o­gy (ASH) meet­ing in early December.

Abstracts for the ASH presentations are now avail­able, although many con­tain pre­lim­i­nary in­­for­ma­tion that will be updated at the meet­ing.

The Beacon’s ASH preview articles are in­tended to highlight the meet­ing's most in­ter­est­ing myeloma-related studies.

The first and second previews, published earlier this week and last week, provide an overview of ASH abstracts about the newest poten­tial mye­lo­ma ther­a­pies just starting out in clin­i­cal trials.  Further previews will …

At this year’s American Society of Hematology (ASH) meeting, which will be held in early De­cem­ber, more than 100 oral pre­sen­ta­tions and about 400 poster pre­sen­ta­tions will summarize re­search focused on multiple myeloma.

Abstracts for these pre­sen­ta­tions are now avail­able.

During the next several weeks, The Beacon will pub­lish a series of arti­cles pre­viewing the myeloma-related studies from the ASH meeting that are of par­tic­u­lar interest.

Each of the articles will cover abstracts related to a specific topic, such as new treat­ments under de­vel­op­ment, current treat­ments, stem cell trans­plan­ta­tion, prog­nos­tic factors, and …

• After initial data read-out in Part 1, study may possibly be expanded and continued in Part 2 for use as a potential registration study
• Patient recruitment expected to start soon

Copenhagen (Press Release) - Genmab A/S (OMX: GEN) announced today that its partner, Janssen Bio­tech, Inc. ("Janssen") will start a new Phase II study of dara­tu­mu­mab in multiple myeloma.  The Phase II study is designed in 2 parts in multiple myeloma patients who have received at least three dif­fer­en­t lines of ther­apy in­­clud­ing both a pro­te­a­some inhibitor and an immuno­modu­la­tory agent (IMiD) or who are double refractory to a pro­te­a­some inhibitor and an IMiD.  This is the same indi­ca­tion for which dara­tu­mu­mab was granted Break­through Therapy Desig­na­tion from the …